Check Cap (CHEK) Downgraded by Zacks Investment Research

Check Cap (NASDAQ:CHEK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, HC Wainwright decreased their price objective on shares of Check Cap from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Tuesday, November 28th.

Shares of Check Cap (CHEK) traded down $0.07 during midday trading on Thursday, hitting $0.72. 174,101 shares of the company’s stock traded hands, compared to its average volume of 385,352. Check Cap has a 52 week low of $0.60 and a 52 week high of $2.38. The stock has a market cap of $13.77 and a price-to-earnings ratio of -1.17.

A hedge fund recently bought a new stake in Check Cap stock. Armistice Capital LLC acquired a new position in Check Cap Ltd (NASDAQ:CHEK) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 748,000 shares of the medical research company’s stock, valued at approximately $651,000. Armistice Capital LLC owned approximately 3.88% of Check Cap as of its most recent SEC filing. Institutional investors and hedge funds own 17.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Check Cap (CHEK) Downgraded by Zacks Investment Research” was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit